Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Breast Cancer

High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation

Bone Marrow Transplantation volume 31, pages 755–761 (2003)Cite this article

Summary:

This study was conducted to evaluate the efficacy of high-dose thiotepa, melphalan and carboplatin (TMCb) regimen in 27 patients undergoing autologous stem cell transplantation (ASCT) for metastatic breast cancer. A total of 27 patients with stage IV breast cancer underwent ASCT following thiotepa (500 mg/m2), melphalan (100 mg/m2) and carboplatin (1200–1350 mg/m2). Of 27 patients, 17 had refractory relapse, eight had responding relapse, and two had no evidence of disease (NED) at the time of transplant. In all, 11 patients had only bone disease, nine had bone plus visceral disease, three had only visceral disease, and two had locoregional recurrent disease. The median time from diagnosis to transplant was 1081 days (range 180–2341). Staging for evaluation of response was performed 4–6 months after transplantation. Five patients were not evaluable (NE) for response because of NED at transplant (n=2) or early death due to transplant-related complications (n=3) (two of viral pneumonia and one of regimen-related toxicity) occurring at a median of 4 days (range 11–46) post-transplant. One of the two patients who was NED at the time of transplant is still NED on day 760 post-transplant. Seven of 15 refractory (47%) and 5/7 (71%) responsive patients with evaluable disease achieved a complete response of all measurable disease or all soft-tissue disease with at least improvement in bone lesions. Of 27 patients (37%),10 are alive and progression-free, a median of 582 days (range 410–1380) after treatment, 6/17 (35%) with refractory disease and 4/10 (40%) with responsive disease. The probability of progression-free survival (PFS) for all patients was 0.50. The probabilities of PFS at 2 years for patients with refractory (n=17) and responsive (n=10) disease were 0.42 and 0.60, respectively. PFS at 2 years for the 14 patients who were NED or achieved CR/PR* following-HDC was 0.67. PFS at 2 years for patients who did not achieve CR/PR* following-DHC was 0.33. These preliminary data suggest that high-dose TMCb followed by autologous stem cell transplantation is an effective regimen for patients with advanced breast cancer and may be comparable to some previously used regimens.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sarosy G, Leyland-Jones B, Soochan P et al. The systemic administration of intravenous melphalan. J Clin Oncol 1988; 6: 1768–1782.

    Article  CAS  PubMed  Google Scholar 

  2. Wright JC, Golomb FM, Gumport SL et al. Summary of results with triethylenethiophosphoramide. Ann NY Acad Sci 1958; 68: 937–966.

    Article  CAS  PubMed  Google Scholar 

  3. Lemaistre CF, Herqıg GP, Herqıg RH et al. High-dose thiotepa and autologous bone marrow rescue for the treatment of breast cancer. Breast Cancer Res Treat 1987; 10: 89.

    Google Scholar 

  4. Maranichi D, Pıana L, Blaise D et al. Phase I–II studies of high-dose alkylating agents in poor risk patients with breast cancer with autologous bone marrow transplant. In: ABMT: Proceedings of the Third International Symposium. Dicke K, Spitzer TR, Jagannath S (eds). University of Texas MD Anderson Hospital: Houston, TX, 1987; 475–480.

  5. Corringham R, Gılmore M, Prentice H et al. High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors. Cancer 1983; 52: 1783–1787.

    Article  CAS  PubMed  Google Scholar 

  6. Weaver CH, Bensinger WI, Appelbaum FR et al. Phase I study of high-dose busulfan, melphalan, and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813–819.

    CAS  PubMed  Google Scholar 

  7. Schiffman K, Bensinger W, Appelbaum F et al. Phase-II of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943–950.

    CAS  PubMed  Google Scholar 

  8. Bensinger W, Schiffman K, Holmberg L et al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant 1997; 19: 1183–1189.

    Article  CAS  PubMed  Google Scholar 

  9. Eder JP, Elıas A, Shea TC et al. A phase I–II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239–1245.

    Article  CAS  PubMed  Google Scholar 

  10. Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651–655.

    Article  CAS  PubMed  Google Scholar 

  11. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–110.

    Article  CAS  PubMed  Google Scholar 

  12. Holland K, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156–1164.

    Article  CAS  PubMed  Google Scholar 

  13. Ayash L, Elias A, Ibrahim J et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 1998; 16: 1000–1007.

    Article  CAS  PubMed  Google Scholar 

  14. Demirer T, Ilhan O, Mandel NM et al. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow Transplant 2000; 25: 697–703.

    Article  CAS  PubMed  Google Scholar 

  15. Demirer T, Buckner CD, Bensinger WI et al. Peripheral blood stem cell (PBSC) collections after taxol, cyclophosphamide and recombinant human granulocyte-colony-stimulating factor (rhG-CSF). J Clin Oncol 1995; 13: 1714–1719.

    Article  CAS  PubMed  Google Scholar 

  16. Demirer T, Buckner CD, Storer B et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte-colony stimulating factor. J Clin Oncol 1997; 15: 684–690.

    Article  CAS  PubMed  Google Scholar 

  17. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood progenitor cells following the administration of cyclophosphamide, etoposide and granulocyte-colony stimulating factor: an analysis of 497 patients. Transfusion 1997; 37: 896–903.

    Article  CAS  PubMed  Google Scholar 

  18. Rowley SD, Bensinger WI, Gooley T et al. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994; 83: 2731–2736.

    CAS  PubMed  Google Scholar 

  19. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  PubMed  Google Scholar 

  20. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043–2049.

    Article  CAS  PubMed  Google Scholar 

  21. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  22. Hyrniuk WM . Relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987; 14: 65–74.

    Google Scholar 

  23. Broder LE, Tormey DC . Combination chemotherapy of carcinoma of the breast cancer. Cancer Treat Rev 1974; 1: 183–203.

    Article  Google Scholar 

  24. Antman K, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–1879.

    Article  CAS  PubMed  Google Scholar 

  25. Demirer T, Buckner CD, Appelbaum FR et al. High-dose busulfan, and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 1996; 17: 769–774.

    CAS  PubMed  Google Scholar 

  26. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368–1376.

    Article  CAS  PubMed  Google Scholar 

  27. Williams SF, Mick R, Desser R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824–1830.

    Article  CAS  PubMed  Google Scholar 

  28. Klumpp TR, Mangan KF, Glenn LD et al. Phase II pilot study of high-dose busulfan and CY followed by autologous BM of peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 1993; 11: 337–339.

    CAS  PubMed  Google Scholar 

  29. Eder JP, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592–1597.

    Article  CAS  PubMed  Google Scholar 

  30. Dunphy FR, Spitzer G, Buzdar A et al. Treatment of estrogen receptor negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207–1216.

    Article  CAS  PubMed  Google Scholar 

  31. Williams SF, Gilewski T, Mick R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743–1747.

    Article  CAS  PubMed  Google Scholar 

  32. Ayash LJ, Wheeler C, Reich E et al. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37–44.

    Article  CAS  PubMed  Google Scholar 

  33. Vaughan WP, Reed EC, Kessinger A et al. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant 1994; 13: 619–624.

    CAS  PubMed  Google Scholar 

  34. Gutierrez-Delgado F, Holmberg LA, Hooper H et al. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer. Bone Marrow Transplant 2000; 26: 51–59.

    Article  CAS  PubMed  Google Scholar 

  35. Antman K, Gale RP . Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med 1988; 108: 570–574.

    Article  CAS  PubMed  Google Scholar 

  36. Berry DA, Broadwater G, Klein JP et al. High-dose versus standard dose chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002; 20: 743–750.

    Article  CAS  PubMed  Google Scholar 

  37. Lotz JP, Cure H, Janvier M et al. High dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: results of the French protocol PEGASE 04. Proc Am Soc Clin Oncol 1999; 18: 43a.

    Google Scholar 

  38. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069–1076.

    Article  CAS  PubMed  Google Scholar 

  39. Madan B, Broadwater G, Rubin P et al. Improved survival with consolidation high-dose CBP compared with observation followed by transplant at relapse in women with metastatic breast cancer and only bone metastases treated with induction AFM: a phase III prospective randomized comparative trial. Proc Am Soc Clin Oncol 2000; 19: 48a(184).

    Google Scholar 

  40. Peters WP, Jones RB, Vredenburgh J et al. A large, prospective, randomized trial of high-dose combination alkylating agent (CBP) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1996; 15: 149a.

    Google Scholar 

  41. Crump M, Gluck S, Stewart D et al. Randomized trial of high-dose chemotherapy with autologous peripheral blood stem cell support compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) Clinical Trials Group Study. Proc Am Soc Clin Oncol 2001; 20: 21a.

    Google Scholar 

  42. Weaver CH, West WH, Schwartzberg LS et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 1997; 19: 661–670.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ankara Numune Education and Research Hospital, Ankara, Turkey

    T Demirer, M Aylı, S Dincer, N Ustael, M Yildiz, T Ustun, G Ozet & O Muftuoglu

  2. Department of Bone Marrow Transplantation Unit, Ankara University Medical School, Ankara, Turkey

    T Demirer, M Aylı, S Dincer, N Ustael, M Yildiz, T Ustun, G Ozet & O Muftuoglu

  3. Department of Hematology and Oncology, Ankara, Turkey

    T Demirer, V A Uysal, O Ilhan, H Koc, M Arat & H Akan

  4. Department of Biostatistics, Ankara, Turkey

    Y Genc

  5. Ankara Oncology Hospital, Ankara, Turkey

    M Daglı & T Fen

  6. Department of Medical Oncology, Gazi University Medical School, Ankara, Turkey

    N Gunel

  7. Department of Internal Medicine, Mersin University Medical School, Ankara, Turkey

    E Seyrek

Authors
  1. T Demirer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V A Uysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Aylı
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Genc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Ilhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Koc
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Daglı
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Arat
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Gunel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T Fen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Dincer
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. N Ustael
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M Yildiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. T Ustun
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. E Seyrek
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. G Ozet
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. O Muftuoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. H Akan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Demirer, T., Uysal, V., Aylı, M. et al. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation. Bone Marrow Transplant 31, 755–761 (2003). https://doi.org/10.1038/sj.bmt.1703918

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703918

Keywords

This article is cited by

Search

Advanced search

Quick links